Sparrow Health System, part of University of Michigan Health, experts release findings in a study of a cancer drug for patients with genetic mutations.

Researchers look into a drug called proxalutamide as a potential therapeutic for the coronavirus.

A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a Michigan Medicine study finds.

Michigan Medicine researchers looked into a drug in development to treat prostate cancer called proxalutamide, which works by blocking an enzyme called TMPRSS2 (transmembrane protease, serine 2) that is regulated by androgen receptors, as a potential therapeutic for COVID.

A study from the University of Michigan Rogel Cancer Center uncovers a new mechanism to explain why some prostate tumors switch from a common, treatable form to a more rare and aggressive form of prostate cancer.

Research finds genetic testing for cancer can bring more knowledge to patients and their relatives, but not many people get it done.

Fourth-year radiation oncology resident Dr. Jamie Takayesu, discusses her research on whether health care providers talk to women receiving radiation for genitourinary cancer about sexual health and function as much as they do men.

Scott Ward’s been through it all: hormone therapy, chemotherapy, radiation, surgery, genetic sequencing, group therapy and more. Now, he’s channeling the roller coaster of his cancer treatment into art.

Biopsies from the same patients before and after treatment reveal how a specific drug reprograms prostate tumors.

Breakthroughs in the field of genomics are revolutionizing prevention, diagnosis and care.

Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.

Nearly 2 decades after a groundbreaking discovery, Arul Chinnaiyan wins a prestigious cancer research award.

A chromatin degrader stops transcription factors from driving cancer, which may serve as a potential treatment approach for over 90% of prostate cancers.

A protein called PIKfyve impacts multiple processes involved in metabolism and cell death; blocking it is key to making immunotherapy work in prostate cancer.

An analysis of patient data from across Michigan found scores from the Decipher Biopsy test independently aligned with outcomes.